NEW YORK (GenomeWeb News) – Cepheid today said that European Union regulatory authorities have cleared the firm’s Xpert HemosIL FII & FV assay for marketing.
 
The assay detects Factor II and Factor V Leiden genetic variations associated with thrombophilia. The test was developed for use on Cepheid’s GeneXpert multiplex molecular diagnostics system.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.